CalciMedica
CALC
About: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Employees: 15
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
0% more funds holding
Funds holding: 30 [Q1] → 30 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
2.77% less ownership
Funds ownership: 29.44% [Q1] → 26.67% (-2.77%) [Q2]
21% less capital invested
Capital invested by funds: $7.49M [Q1] → $5.93M (-$1.57M) [Q2]
Financial journalist opinion
